High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass.
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus.Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines.Mechanical-tactile stimulation (MTS) intervention in a neonatal stress model improves long-term outcomes on boneModulation in Wistar rats of blood corticosterone compartmentation by sex and a cafeteria dietAdvances in glucocorticoid-induced osteoporosisThe association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis.Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study.Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus.Glucocorticoid-induced bone loss is associated with abnormal intravertebral areal bone mineral density distribution.Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronateGlucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos).Role of the hypothalamus in the neuroendocrine regulation of body weight and composition during energy deficit.Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.Advances in treatment of glucocorticoid-induced osteoporosis.The Alara Metriscan phalangeal densitometer: evaluation and triage thresholds.Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.Prevalence and risk factors associated with low-impact fractures in men with rheumatoid arthritis.Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.Bone geometry, volumetric bone mineral density, microarchitecture and estimated bone strength in Caucasian females with systemic lupus erythematosus. A cross-sectional study using HR-pQCT.
P2860
Q28074148-4BC12EE6-39E6-4835-BEE4-CA1874C3B1B3Q30946308-0F81DBA1-4BE7-467E-B27B-84F970860B6AQ33375577-9C43C606-6D54-45D9-A2AB-78B67C19B7DDQ33793850-0B6AB7E4-0F04-4346-B72F-16CC91AA2271Q34008357-712926A6-6394-4C55-B7AB-AA9D8D87756AQ34603414-758A37FF-5237-4102-BB72-B07ACBA502A0Q34975913-E9162F3E-60F1-4A34-A0E8-F1B31D740EFDQ35099938-4CAE3314-096C-4BF3-B55F-8509169AFA19Q35156177-E254451D-267E-4741-BFB9-6E66F8744C8AQ36517231-E6CB22B5-214E-4D08-9399-8FB780CA6E84Q36869575-419D8F28-0A3F-41A9-8695-5B85024BEC1EQ37230770-85270D63-1B66-4092-84D0-07487217F003Q37418453-48527F7E-59B1-4259-B9C3-F534F8AB8D6AQ37954380-DB263D78-4849-4E52-ADB6-6821B49E9CB3Q38073889-47E839C7-FA08-4551-900D-0E81701C1F58Q38600333-1437AA01-44F3-4A8A-8AEF-5817536CD628Q39851694-402042CC-CF2F-423D-87EE-3D2CEE9C7182Q40127247-1F645D63-8BC1-4FC2-9E35-75CCA767FA33Q44251450-C30CB974-894E-4D93-8C16-29FC8658D5F3Q44427353-ACE92FB3-1BA9-4776-AA3C-F5B55FC4D49BQ44453411-B7AFA60C-C054-4180-A2B5-FBD2ACA4FC0FQ48046622-6DBC43E2-A0A0-4878-8A28-963B8EE49D9DQ52729477-1C9D165A-0D11-4109-A3A5-5D162610B6ECQ53044805-7892DD95-0065-4599-B10D-A06DEA0F82F7
P2860
High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
High-dose glucocorticoid treat ...... al density and lean body mass.
@ast
High-dose glucocorticoid treat ...... al density and lean body mass.
@en
type
label
High-dose glucocorticoid treat ...... al density and lean body mass.
@ast
High-dose glucocorticoid treat ...... al density and lean body mass.
@en
prefLabel
High-dose glucocorticoid treat ...... al density and lean body mass.
@ast
High-dose glucocorticoid treat ...... al density and lean body mass.
@en
P2093
P1476
High-dose glucocorticoid treat ...... al density and lean body mass.
@en
P2093
Akihiro Yasoda
Kazuwa Nakao
Kiyoshi Tanaka
Koshi Natsui
Michio Suda
Shoichi Ozaki
Yoko Sakuma
P2888
P304
P356
10.1007/S00198-005-1923-3
P407
P577
2005-05-11T00:00:00Z
P6179
1010083299